Lucid Diagnostics (LUCD) Shares Outstanding (Diluted Average) (2022 - 2025)

Lucid Diagnostics has reported Shares Outstanding (Diluted Average) for 4 years, with the latest figure at $92.1 million in Q3 2025.

• For the quarter ending Q3 2025, Shares Outstanding (Diluted Average) rose 82.89% year-over-year to $92.1 million; the trailing twelve-month figure through Sep 2025 stood at $92.1 million (up 82.89% YoY), and the FY2024 full-year result was $50.5 million, up 20.98% from the prior year.
• Shares Outstanding (Diluted Average) for Q3 2025 stood at $92.1 million, up from $84.0 million in the prior quarter.
• The five-year high for Shares Outstanding (Diluted Average) was $92.1 million in Q3 2025, with the low at $35.4 million in Q2 2022.
• Historically, Shares Outstanding (Diluted Average) has averaged $50.9 million across 4 years, with a median of $43.4 million in 2023.
• Annual changes were most pronounced in 2024 — Shares Outstanding (Diluted Average) climbed 9.87% — and 2025, when it jumped 82.89%.
• Lucid Diagnostics' Shares Outstanding (Diluted Average) stood at $36.2 million in 2022, then advanced by 15.44% to $41.8 million in 2023, then rose by 20.98% to $50.5 million in 2024, then jumped by 82.38% to $92.1 million in 2025.
• The last three Shares Outstanding (Diluted Average) figures came in at $92.1 million (Q3 2025), $84.0 million (Q2 2025), and $68.8 million (Q1 2025), per Business Quant data.